← All trials
NCT05516628
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 31, 2022
- Primary completion
- Oct 31, 2026
- Completion date
- Oct 31, 2026
- First posted
- Aug 25, 2022
- Last posted
- Sep 30, 2022
- Enrollment
- 30
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Government of SingaporeLead sponsor
- Cancer Science Institute of SingaporeCollaborator
- Changi General HospitalCollaborator
- Duke UniversityCollaborator
- National University of SingaporeCollaborator
- National University of SingaporeCollaborator
- Nanyang Technological UniversityCollaborator
- Government of SingaporeOverall official - principal investigator
- National University of SingaporeCollaborator
- Sengkang General HospitalCollaborator
- Singapore Clinical Research InstituteCollaborator
- Singapore General HospitalCollaborator
- National University of SingaporeCollaborator
- Nanyang Technological UniversityCollaborator
- Government of SingaporeOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.